Lung Cancer in the Elderly

Gridelli, Cesare; Langer, Corey J.; Maione, Paolo; Rossi, Antonio; Schild, Steven E.

doi:10.1200/jco.2006.10.3085

Cited by 142 publications

(109 citation statements)

References 84 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…2 NSCLC accounts for about 85% of all cases of lung cancer. 3 Conventional treatments for lung cancer involve surgery, chemotherapy and radiotherapy. Unfortunately, the poor 5-year survival rate of patients with lung cancer (only 14%) has not been improved by current treatments primarily due to a propensity to metastasize as well as resistance to chemotherapy and radiation.…”

Section: Introductionmentioning

confidence: 99%

Enhanced tumor suppression by an ING4/IL-24 bicistronic adenovirus-mediated gene cotransfer in human non-small cell lung cancer cells

Zhu

Xie

et al. 2011

Cancer Gene Ther

View full text Add to dashboard Cite

ING4 as a member of inhibitor of growth (ING) tumor suppressor family has potent inhibitory effects on a variety of tumors. Interleukin-24 (IL-24), a cytokine-tumor suppressor, also shows broad-spectrum and tumor-specific antitumor activities. In this report, we constructed an ING4/IL-24 bicistronic adenovirus (Ad-ING4-IL-24) and assessed its combined effect on in vitro and in vivo A549 human non-small cell lung cancer cells. We demonstrated that ING4 and IL-24 combination treatment by adenovirusmediated ING4 and IL-24 coexpression induced additive growth suppression and apoptosis as well as an overlapping effect on upregulation of P21, P27, Fas, Bax and cleaved Caspases-8, 9, 3 and downregulation of Bcl-2 in in vitro A549 lung carcinoma cells. Moreover, Ad-ING4-IL-24 treatment additively inhibited in vivo A549 lung carcinoma subcutaneous (s.c.) xenografted tumor growth and reduced CD34 and microvessel density in A549 xenografted tumors in athymic nude mice. The enhanced antitumor activity elicited by Ad-ING4-IL-24 was closely associated with the coordinate activation of extrinsic and intrinsic apoptotic pathways and additive inhibition of tumor angiogenesis. Thus, our results indicate that cancer gene therapy combining two or more tumor suppressors such as ING4 and IL-24 may constitute a novel and effective therapeutic strategy for lung carcinoma and other cancers.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced tumor suppression by an ING4/IL-24 bicistronic adenovirus-mediated gene cotransfer in human non-small cell lung cancer cells

Zhu

Xie

et al. 2011

Cancer Gene Ther

View full text Add to dashboard Cite

show abstract

“…The schedule chosen for docetaxel was 37.5 mg m À2 on days 1 and 8 every 3 weeks according to our previous study carried out in elderly patients in a second-line setting (Tibaldi et al, 2006;Gridelli et al, 2007b).…”

mentioning

confidence: 99%

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

Tibaldi¹,

Vasile²,

Antonuzzo

et al. 2008

Br J Cancer

View full text Add to dashboard Cite

This multicenter phase II study evaluated, in chemonaive patients with stage IIIB -IV NSCLC, age X70 and with a performance status 0 -2, the activity, efficacy and tolerability of planned sequential administration of gemcitabine 1200 mg m À2 on days 1 and 8 every 3 weeks for three courses followed by three cycles of docetaxel 37.5 mg m À2 on days 1 and 8 every 3 weeks, provided there was no evidence of disease progression. A total of 56 patients entered the study. According to intention-to-treat analysis, the objective response rate was 16.0% (95% CI 7.6 -28.3%); 23 patients (41.0%) had stable disease and 24 patients (43%) had progressive disease. Five patients who had a stable disease after three courses of gemcitabine obtained a conversion to partial response by docetaxel. Median time to progression was 4.8 months (95% CI 3.6 -6.0 months) and median duration of survival was 8.0 months (95% CI 5.6 -10.5 months). The 1-year survival rate was 34%. No grade 4 haematological toxicity was observed and grade 3 neutropenia and thrombocytopenia were reported in 5.4 and 3.6% of the patients, respectively. Grade 3/4 mucositis and grade 3 diarrhoea, both occurred in 3.6% of the patients and grade 3 asthenia was observed in 9% of patients. One patient reported a grade 4 skin toxicity. No treatment-related deaths occurred. Sequential gemcitabine and docetaxel is a well-tolerated and effective regimen in elderly advanced NSCLC patients.

show abstract

“…More than two-thirds of patients who succumb to lung cancer in the United States are over 65 years old (7). Elderly patients tolerate chemotherapy poorly and need novel therapeutic agents.…”

Section: Introductionmentioning

confidence: 99%

Targeted therapies in small cell lung cancer (Review)

Wang

Mao

2012

Oncol Lett

View full text Add to dashboard Cite

Abstract. Lung cancer is the leading cause of cancer-related mortality. Small cell lung cancer (SCLC) accounted for 12.95% of all lung cancer histological types in 2002. Despite trends toward modest improvement in survival, the outcome remains extremely poor. Chemotherapy is the cornerstone of treatment in SCLC. More than two-thirds of patients who succumb to lung cancer in the United States are over 65 years old. Elderly patients tolerate chemotherapy poorly and need novel therapeutic agents. Targeted drugs have less toxicity than chemotherapy drugs, but no targeted agents have been approved for use in the treatment of SCLC patients to date. Certain new targeted agents, including gefitinib, bevacizumab and Bcl-2 inhibitors, offer a promise of improved outcomes, however negative results are more commonly reported than positive. This review focuses on targeted therapies in SCLC.

show abstract

Lung Cancer in the Elderly

Abstract: With the exception of advanced NSCLC, prospective elderly-specific studies are lacking. Available data suggest that outcomes in the fit elderly mirror results observed in younger patients, although toxicity is generally worse.

Cited by 142 publications

References 84 publications

Enhanced tumor suppression by an ING4/IL-24 bicistronic adenovirus-mediated gene cotransfer in human non-small cell lung cancer cells

Enhanced tumor suppression by an ING4/IL-24 bicistronic adenovirus-mediated gene cotransfer in human non-small cell lung cancer cells

First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study

Targeted therapies in small cell lung cancer (Review)

Contact Info

Product

Resources

About